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Introduction and objectives: Novel biomarker research is vital for the progression of 
safe and thorough diagnostic medicine. There is now a need to improve the diagnosis 
of bladder cancer via a noninvasive urine test while balancing the risks of harm from 
investigational procedures, such as cystoscopy and radiological tests, against the like-
lihood of malignancy. We evaluate the diagnostic accuracy and sensitivity of Uro17™ 
urinary biomarker for the detection of urothelial cancer in hematuria patients in a 
prospective blinded validation study. Uro17™ is an immunobiomarker which binds 
to the oncoprotein Keratin 17, which is involved in the replication cycle of malig-
nant cells. This study compared cystoscopic and histological investigations against 
Uro17™ results in patients being investigated for symptoms of urothelial cancer.
Materials and methods: After receiving both local and national ethics/protocol ap-
proval, 71 patients were consented and recruited into the study. All patients were 
scheduled to undergo cystoscopic investigation, and following recruitment, a urine 
sample was collected. Urine samples were anonymized and processed as per stand-
ard cytology protocols and stained using Uro17™ immunobiomarker. The patholo-
gists assessing the results were blinded to the patient and background history, and 
the results were compared to the biopsy histology.
Results: The full cohort of enrolled patients consisted of 71 participants included. 
There were 55 males and 16 females, with an average age of 70. Thirteen were cur-
rent smokers, 42 ex-smokers, and 16 nonsmokers. The malignancies detected in-
cluded both muscle-invasive (n = 6) and non-muscle-invasive tumors (n = 38), and 
tumors of all grades and carcinoma in situ. Uro17™ was shown to have an overall 
sensitivity of 100% and a specificity of 92.6%, with a positive predictive value of 
0.957 and negative predictive value of 1. Uro17™ investigation was positive in every 
case of urothelial malignancy.
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1  | INTRODUC TION AND OBJEC TIVES
Annually, there are over 197 000 new diagnosis of bladder cancer 
in Europe and 430 000 globally, making it the fourth most preva-
lent malignancy in men and the fifth most prevalent in women.1,2 
Prognosis and mortality is strongly correlated with cancer staging 
at the time of diagnosis, with muscle invasion (T2-4) resulting in a 
significant increase in mortality.3 Unfortunately, 37% of new cases 
are found to have muscle-invasive malignancies at the time of di-
agnosis which can result in a 60% 5 year survival rate, dropping to 
4% for metastatic malignancy.4 However, new developments in the 
management of both nonmetastatic and metastatic disease continue 
with improvement in survival.4,5 This emphasizes despite of the new 
developments is on the importance of early diagnosis and timely 
treatment, being the clear clinical priority.
The UK currently does not currently have a screening program 
for bladder cancer. In a majority of patients the diagnosis and in-
vestigations for bladder cancer rely on symptomatic presentation to 
general practice (Visible/Non-visible hematuria) or incidental find-
ings. The UK National Institute of Health Care and Excellence (NICE) 
guidance recommends that community physicians refer urgently to 
the urology department for suspected bladder cancer based upon 
symptoms of hematuria and age, shown in Table 1.6
While visible hematuria is a significant predictor of bladder can-
cer, associated with an odds ratio of 34, the detection rate of ma-
lignancy in patients who present with visible hematuria has been 
reported as 18.9%, making this symptom not only nonspecific, but 
also less sensitive, and differential diagnoses may result in uncer-
tainties or delays in referrals from primary care.7 Visible hematuria 
has been shown to only be present in around half of bladder can-
cer cases, and other symptoms are nonspecific, such as abdominal 
pain and constipation, or even potential “red herrings” such as raised 
inflammatory markers and urinary tract infections.8 There is a clear 
need for improved diagnostic methods, especially for patients with 
bladder cancer who may present without visible hematuria.3
The gold standard for investigation of bladder cancer is cystos-
copy, as this allows direct visualization of the urothelial lining of the 
urethra and bladder, however, this is uncomfortable for the patient 
and does not allow investigation of the upper tracts.9 Cystoscopy is 
often paired with radiological scanning such as CT urography to as-
sess for upper urinary tract disease. This is usually performed during 
the first encounter that the patient has with the urology service, re-
sulting in a significant number of patients unnecessarily undergoing 
both radiation exposure and invasive procedures, which can lead 
to further complications such as urinary tract infections.10,11 These 
cases of unnecessary investigations for bladder cancer result in sig-
nificant costs, estimated to be over £100 million annually in the UK 
alone.12
Following treatment for diagnosed bladder cancer, follow-up by 
means of cystoscopic surveillance is required for many years. For 
non-muscle-invasive bladder cancer (NMIBC), the 3 year total costs 
per person for surveillance alone are estimated to be over £4500, 
with additional costs for any recurrence or progression.13
Risk grouping/stratifying models, probability nomograms, and 
artificial neural networks are all methods by which urologists have 
hoped to reduce the amount of unnecessary investigations that are 
performed and to help better focus resources on patients who truly 
require them.14 However, these methods, no matter how much col-
lective data are inputted, are generic and not patient specific, and 
will therefore result in some patients being incorrectly stratified.
As research into the molecular biology of bladder cancer has pro-
gressed, genetic markers have been identified in the tumorigenesis 
and progression of the disease.15 This research has translated into 
identifiable biomarker that could be used to identify bladder cancer 
Conclusions: Our current data indicates Uro17™ is a highly sensitive noninvasive 
bladder cancer urine detection test that can improve the diagnosis of Bladder cancer. 
This can further improve diagnostic capabilities in primary care, reduce the number 
of referrals to Urology department, and reduce the number of unnecessary invasive 
procedures for new patients with a suspected urinary bladder cancer.
K E Y W O R D S
biomarker, bladder cancer, cytology, diagnostic, oncology
Age criteria Symptom criteria
Aged 45 and over Unexplained visible hematuria without urinary tract 
infection
Aged 45 and over Visible hematuria that persists or recurs after 
successful treatment of urinary tract infection
Aged 60 and over Unexplained non-visible hematuria and either 
dysuria or a raised white cell count on a blood test
TA B L E  1   NICE Referral guidelines for 
suspected bladder cancer6
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from urine or blood samples. Urine samples lend a significant advan-
tage as they will be in physical contact with any malignancy and are 
easily obtainable.
A need for an inexpensive diagnostic test or screening tool has 
been expressed repeatedly.7,12,16 In 2008, there were six urine-based 
biomarkers FDA cleared/approved for the surveillance of bladder can-
cers which were reviewed by Herman et al., but these were all found to 
have sensitivities equal to or only slightly greater than cytology alone.17
In 2013, Casadio et al. investigated cell free DNA in urine sam-
ples as a potential biomarker.18 It was shown to have a high predic-
tive value for early NMIBC with sensitivity of 0.73 and specificity 
of 0.83, but due to being a specialized investigation and having high 
processing costs, it was unsuitable to be used as a feasible screening 
or diagnostic tool.18
A biomarker that has been researched extensively is the nuclear 
matrix protein NMP22, which is involved in mitosis and is often raised 
in urine samples where malignancy is present. The test is performed 
using monoclonal antibody testing with ELISA meaning that it could 
be accessible and affordable on a large scale. A meta-analysis of 19 
trials was performed by Wang et al. which showed sensitivity and 
specificity were 56% (52%-59%) and 88% (87%-89%), respectively.19
UroVysion™ is another FDA-approved urinary test from recent 
literature. It functions by utilizing fluorescent in situ hybridization 
(FISH) to identify chromosomal abnormalities characteristic of blad-
der cancer such as deletion 9p21 and alterations to chromosome 3, 
7, and 17.20 FISH requires gene-specific probes to allow detection of 
these genetic changes, and then, direct visualization with the use of 
a fluorescent microscope which, while costing less that cystoscopy, 
is relatively high cost when compared with other biomarkers. It also 
requires specialist personnel to interpret results.
Keratin 17 (K17) is a member of cytokeratin family of proteins 
normally expressed in hair follicles and nail beds.21 Previous studies 
have shown that K17 is an oncoprotein associated with poor prog-
nosis in tumorigenesis of many malignancies including cervical, en-
dometrial, esophageal, lung, and bladder.22–24 K17 has already been 
investigated for its biomarker possibilities for the detection and 
prognosis of cervical cancer.24
Recently, Babu et al. performed a study looking at K17 in urothe-
lial carcinomas and showed that K17 is expressed in urothelial car-
cinomas at levels of 2.5 to 8 log fold greater than normal urothelial 
mucosa, making it a promising biomarker for bladder cancer.25 In 
this study, analysis of biopsy tissue blocks showed that K17 was ex-
pressed in all grades and stages of urothelial cancers tested (PUC-LG, 
PUC-HG, and UC).25 More importantly, this study also examined the 
expression of K17 in urine cytology samples from 112 patients un-
dergoing routine bladder cancer monitoring and the study showed 
that K17 has sensitivity of 100% and specificity of 96% in identifying 
patients with recurrent urothelial cancers. However, in the study, 
expression of K17 in newly diagnosed cancers from an hematuria 
population was not examined.
F I G U R E  1   Study design flowchart
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In the current study, we for the first time report the result of K17 
expression in urine cytology samples from hematuria patients with 
no prior history of urothelial cancer to evaluate application of K17 in 
identifying urothelial cancer in patients with hematuria.
2  | PATIENTS AND METHODS
2.1 | Aims and objectives
The aim of this trial was to investigate and measure the accuracy and 
precision of the urinary bladder cancer test, URO17™, which uses 
K17, when compared with the gold standard of rigid cystoscopy and 
bladder biopsy, in new diagnosis of bladder cancer in hematuria pa-
tients without a prior history of bladder cancer.
2.2 | Study design
The study was designed as a prospective blinded validation trial with 
71 participants who were under investigation for new diagnosis of 
urothelial tract cancer. The study was performed at East and North 
Herts NHS Trust using input from Urologists, Pathologists, R&D 
Department, and patient advocates. Study design is demonstrated 
in Figure 1.
2.3 | Ethics approval
Local ethics approval gained through R&D departmental procedure. 
IRAS Application 253585 submitted and national ethics/protocol 
approval received (18/EE/0395).
2.4 | Inclusion and exclusion criteria
Inclusion:
•	 Patients	aged	≥18	years	of	age;
• Patients under investigation for bladder cancer due to undergo 
investigative standard of care biopsy.
Exclusion:
• Patients aged <18 years of age;
• Patients with catheter in situ;
• Patients who are currently undergoing radiation therapy;
• Proposed subject has no bladder (due to surgical removal);
• Patients unable or unwilling to provide consent;
• Patients currently on investigational drug trials.
As the inclusion criteria required patients to be undergoing cys-
toscopy & biopsy for histological analysis and comparison, and as 
our trust utilizes One Stop Clinic Services, the meant that patients 
had likely already undergone flexible cystoscopy prior to study re-
cruitment. The inclusion criteria were developed this way to ensure 
that full histological analysis was performed thus reducing possible 
surgeon variability.
2.5 | Data collection
Following consenting and recruitment, a urine sample was collected 
from each participant and the following data were collected; gender; 
age; weight, height, and BMI; smoking status; previously diagnosis of 
bladder cancer (staging and treatments provided); urine sample first 
morning void status; urine sample volume; and urine sample hematu-
ria by routine dipstick. Subsequent cancer diagnosis will be collected 
for participants for a period of 5 years via review of available patient 
medical records.
2.6 | Urine sample preparation
Urine samples were anonymized, stored at 4°C and underwent cen-
trifugation on a Sorvall ST 16 Centrifuge (Thermo Scientific) at 1500 
r.p.m. for 5 minutes. The supernatant was discarded, and the pelleted 
cell deposits were then inspected. If the deposit was hardly visible, a 
vial of PreservCyt fluid (Hologic) was added into the Universal con-
tainer, the contents mixed and tipped back into the PreservCyt vial. 
If the deposit was large but not excessively bloodstained, then, the 
deposit was mixed using a Pasteur pipette, three drops were added 
to the PreservCyt vial. If the deposit was excessively blood stained, 
then, 15 mL of CytoLyt fluid (Hologic) was added to the deposit to 
wash the sample (this lyses the blood) and the sample underwent 
centrifugation for 10 minutes at 1500 rpm and three drops of the 
deposit was added to a PreservCyt vial.
Samples were processed on an automated ThinPrep 2000 pro-
cessor (Hologic) using non-gynecological blue filters. This proces-
sor generates a ThinPrep slide with a monolayer of cells. Slides 
were then fixed with Cytofix spray (Hologic) and allowed to dry 
for 15 minutes.
Sample slides were stored between 2-8°C and stained in weekly 
batches using URO17™ (Lot: A8034124, 3.42 mg/mL, 1:5000 dilu-
tion in 10% CS) on a Leica detection kit DS9800 for 20 minutes.
2.7 | Diagnostic test evaluation
The URO17™ staining results were analyzed by two blinded patholo-
gists (SA and RS) simultaneously and results scored as per scoring 
system in Table 2. No patient information, including any previously 
diagnosed malignancy of treatments, was available to the pathology 
team.
Biopsy histology was performed through the SOC route with no 
evidence on pathology request systems that patients were part of 
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the trial and were reported according to TNM staging and grading as 
per WHO classification. This histological data were collected by the 
research team once URO17™ results had been provided.
3  | RESULTS
3.1 | Patient demographics
In the patient cohort (71 included participants), there were 55 males 
and 16 females, with an average age of 70. 13 (18.31%) were cur-
rent smokers, 42 (59.15%) ex-smokers, and 16 (22.54%) nonsmokers, 
shown in Table 3. The malignancies detected included six muscle-in-
vasive and 38 non-muscle-invasive tumors, and tumors of all grades (9 
G1, 14 G2, 18 and G3) and four cases of carcinoma in situ, see Table 4.
3.2 | URO17 results
URO17™ and white light cystoscopy + biopsy results are shown in 
Table 5. In patients with no previously diagnosed bladder cancer 
(n = 71), URO17™ was shown to have a sensitivity of 100% and had 
a specificity of 92.6%. There was a positive predictive value (PPV) of 
0.957 and a negative predictive value (NPV) of 1. URO17™ investi-
gation was positive in every case of urothelial malignancy no matter 
the grade or stage. Smoking status, hematuria, and sample volume 
had no impact on staining efficacy.
As per the pathology scoring system, Table 2, weak staining 
cases were classified as negative results. These were specifically 
reviewed to ensure the scoring system was suitable. Twelve cases 
were scored with a weak staining, all 12 were negative biopsy re-
sults. No interobserver variability was identified between the two 
pathologist reporting the URO17™ results.
CT Urogram (Triple phase) imaging was performed for every pa-
tient as per SOC, 36 had radiological findings clinically suggestive of 
malignancy of which 28 (77.8%) had positive histology from bladder 
biopsy. URO17™ was positive in all of the 28 confirmed malignancy 
cases and was clinically correct in 35 of the 36 radiologically positive 
cases (97.2%).
4  | DISCUSSION
This study confirms that URO17™ detected every case of malig-
nancy, no matter the stage, or type of cancer present. A negative 
predictive value of 1 raises the potential for a significantly effective 
screening program/referral tool, knowing that URO17™ negative re-
sults can be heavily relied upon can significantly reduce the number 
of unnecessary invasive procedures performed. Our results support 
previous laboratory studies of K17 which reported sensitivity of 
100% and specificity of 96%.25
This cohort had a significantly high proportion of malignancy 
compared to the expected detection rate in visible hematuria cases. 
As this study required rigid cystoscopy and biopsy for histological 











Visible hematuria samples 11 (15.49%)
Mean sample volume (mL) 20
TA B L E  4   Malignancies detected
Patients with 







TA B L E  5   URO17™ and cystoscopy + biopsy results
(n = 71)




URO17™ (+) 44 2
URO17™	(−) 0 25
TA B L E  2   URO17™ pathology scoring 
system Score
0—Negative No stained cells present
1—Negative Weak staining (1+)
2—Positive Strong staining (2+ and above) >20 positive staining of cells based 
on staining intensity
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analysis, the cohort of patients must have been seen by an urologist 
in one stop clinic, and most of which would have undergone a flexi-
ble cystoscopy. We recognize that this will have resulted in hematu-
ria patients not being suitable for the study as malignancy may have 
been excluded by flexible cystoscopy but as URO17™ was a novel 
biomarker, there was an ethical desire to avoid patients undergoing 
procedures outside of their standard of care. The reassuring data 
from this trial will influence the design of future larger scale studies 
and hopefully Ethic Committees will have less issue with patients 
undergoing cystoscopy based upon URO17™ results.
The patient cohort showed significant level of visible hematuria 
in their specimen samples, but as this cohort was derived from new 
patients under investigation, and as the laboratory protocol uses 
CytoLyt fluid in slide preparation to counteract this, this should not 
impact the URO17™ test results.
A significant amount of recent biomarker research has been fo-
cused on aiding in the surveillance follow-up of known bladder can-
cers.26–28 Unfortunately, as biomarkers are often highly sensitive 
and can provide a positive result before it is cystoscopically visible, 
“anticipatory positive results,” the cost effectiveness of combined 
biomarker-cystoscopy surveillance, have been shown to be worse 
than cystoscopy alone.26 Focusing on screening adjunct applications 
for biomarkers with high sensitivity and NPV, such as URO17™, is 
more likely to result in them becoming cost efficient and valuable 
adjuncts to both primary and secondary care.
It is important to highlight the significance of these results in 
comparison to other urinary biomarkers for bladder cancer.5,19,29–33 
We have confirmed that URO17™ has one of the highest sensitivity 
and specificity reported in identifying bladder cancer through non-
invasive urine samples. Unlike other nucleic-based bladder cancer 
biomarker tests that are complex and expensive to run, URO17™ 
test is an immunocytochemical assay that utilize the same cytol-
ogy samples that are used in urine cytology. The test is also easily 
adaptable to the standard IHC instrumentations and reagents that 
are readily available and familiar in most laboratories which will make 
the test very a cost-effective perform. Furthermore, having a same 
pathologist who usually interpret urine cytology samples also inter-
pret URO17 test will provide efficient workflow and increased util-
ity for urine cytology. While many will see URO17™ as yet another 
biomarker in a myriad of new noninvasive investigations for blad-
der cancer, this study confirms the original finding by Babu et al25 
and expands the application of URO17™ to hematuria patients. In 
the end, combinations of biomarkers may be the key to providing 
the most effective investigation where the application of URO17™ 
will play a major role, and continued research into this must be en-
couraged with the aim of improving patient diagnostics. We will be 
following all patients in the study up for 5 years to evaluate those pa-
tients who may develop a urological malignancy in due course with a 
current URO17™ result.
This current data suggest that URO17™ could be a sensitive and 
specific test to detect PUNLMP and both papillary and nonpapillary 
carcinomas which could potentially providing diagnostic utility in 
cases where it could help identify lesions that can be easily missed 
by traditional urine cytology. Furthermore, the data also showed that 
URO17™ test was able to detect BC in renal pelvis that was missed by 
urine cytology and cystoscopy which suggest that URO17™ test could 
be used to augment and increase the accuracy of cystoscopy and tra-
ditional urine cytology in monitoring patients for recurrence. 5,25.5
This trial was developed with the aim of testing the applicability 
of URO17™ as a real-world biomarker for urinary tract malignancy, 
and therefore, must include all types of patients and malignancy who 
undergo urological investigations. We constructed this prospective 
trial in such a way as to allow predictable clinical variabilities, such 
as urine sample size and sample hematuria, as well as to eliminate 
confounding factors, such as the skill of a pathologist who may de-
tect non-biomarker-related signs in specimens if aware of the back-
ground of the patient. As the test uses standard immunostaining 
available to most pathology departments, we demonstrated that 
this test could be used by any department/laboratory with minimal 
difficulties or additional setup.
The next stage of investigation for URO17™ to be rolled out as a 
screening program would be a large scale, multisite thorough testing 
to demonstrate these promising results on a national scale.34
5  | CONCLUSION
This study indicates that URO17™ is a highly sensitive (100% in this 
study) minimally invasive bladder cancer urine biomarker detection 
test that could help screen patients for bladder cancer in the com-
munity with minimal resources required. This can improve world-
wide diagnostic capabilities in primary care, efficiently triage patient 
referrals to Urology department, and could reduce the number of 
procedures that patients under investigation must go through.
URO17™ urine immunostaining can accurately exclude urothe-
lial malignancy with minimal requirements and will indicate which 
patients that should be thoroughly investigated. While it would not 
replace cystoscopy as the gold standard, and histological analysis is 
still required for staging, URO17™ is an effective adjunct that can 
help reduced the number of unnecessary cystoscopies in hematuria 
patients and screen high-risk patients in the community.
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